Amyloidosis Treatment Market Worth $6.7 Billion by 2025 | CAGR: 7.2%: Grand View Research, Inc.

Monday, November 19, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN FRANCISCO, November 19, 2018 /PRNewswire/ --

The global amyloidosis treatment market size is expected

to reach USD 6.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a 7.2% CAGR during the forecast period. Several factors such as increased adoption of novel targeted therapies and transplantations,
emergence of biologics, and rising geriatric population are driving the market.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Amyloidosis is a group of rare diseases where misfolded aggregates of proteins (amyloids) buildup in tissues and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority of cases, the disease is diagnosed in people over the age of 60, there are a few cases of people being diagnosed in their late 20s and about two-thirds of the patients are male.

Among treatments, chemotherapy held the largest share in 2017, followed by targeted therapy, and supportive care. However, targeted therapies are expected to dominate the market in 2025, supported by a strong pipeline and potential approval of drugs such as Alnylam's Onpattro, Ionis' Tegsedi, Johnson & Johnson's Darzalex, and Takeda's Ninlaro.

Stem cell transplants and targeted therapies are gaining traction in developed countries. However, amyloidosis cohorts in endemic regions do not have access to sufficient healthcare infrastructure to ensure prompt diagnosis and treatment in underdeveloped countries. Chemotherapy and supportive care are anticipated to lose market share over the forecast period due to adverse side effects and lower efficacy.

Browse full research report with TOC on "Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts, 2018 - 2025"at: https://www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market

Further Key Findings From the Report Suggest: 

  • An estimated 16,000 people in U.S. suffer from amyloidosis, with approximately 3,000 to 4,000 new cases being reported annually
  • U.S. dominated the global amyloidosis treatment market, with a share of more than 27.0% in 2017 due to potential launch of pipeline drugs, increased adoption of novel therapeutics, and high cost of treatment in the country
  • Chemotherapy dominated the amyloidosis treatment market, with a share of about 35.0% in 2017. Targeted therapies are projected to witness double-digit growth during the forecast period due to multiple product approvals
  • Emerging markets for amyloidosis such as China, Sweden, Portugal, Turkey, South Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show attractive growth over the forecast period due to improved healthcare infrastructure, favorable government policies, increased investment, and large amyloidosis cohort
  • Alnylam, Ionis, Pfizer, Johnson & Johnson and Takeda are some of the key players operating in this market
  • Currently, 19 products are under evaluation for amyloidosis treatment in various stages of clinical development. Promising pipeline candidates such as Onpattro, Vyndaqel, Tegsedi, Darzalex, and Ninlaro are expected to generate significant revenue upon launch.

Browse related reports by Grand View Research: 

  • Pharmaceutical Packaging Market - The global pharmaceutical packaging market size was valued at USD 77.65 billion in 2016.
  • Erythropoietin (EPO) Drugs Market - The global erythropoietin (EPO) drugs market size was valued at USD 7.4 billion in 2016 and is expected to witness CAGR of 11.5% during the forecast period. 
  • Radiodermatitis Market - The global radiodermatitis market size was estimated at USD 310.9 million in 2016 and is anticipated to grow at a CAGR of 4.0% throughout the forecast period. 
  • Prostate Cancer Therapeutics Market - The global prostate cancer therapeutics market size was valued at USD 7.9 billion in 2016 and is expected to grow at a CAGR of 4.8% over the forecast period.

Grand View Research has segmented the global amyloidosis treatment market based on treatment and country: 

  • Amyloidosis Treatment Outlook (Revenue, USD Million, 2017 - 2025) 
    • Chemotherapy
    • Supportive care
    • Surgery
    • Stem Cell Transplant
    • Targeted Therapy
  • Amyloidosis Treatment Country Outlook (Revenue, USD Million, 2017 - 2025) 
    • U.S.
    • Japan
    • U.K.
    • Germany
    • France
    • Spain
    • Italy

Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

SOURCE Grand View Research, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store